160 results about "Nicotinuric acid" patented technology

Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.

The invention relates to compound premix feed for laying quails, which comprises 3 to 7 kg of manganous sulfate, 2 to 6 kg of zinc sulfate, 1 to 5 kg of ferrous sulfate, 0.2 to 0.6 kg of copper sulphate, 15 to 21 kg of choline chloride, 3 to 7 kg of lysine, 26 to 34 kg of methionine, 1.6 to 2.4 kg of phytase, 180 to 261.2 kg of calcium carbonate, 240 to 310 kg of calcium hydrophosphate, 320 to 440 kg of fish meal, 35 to 65 kg of common salt, 0.26 to 0.85 kg of vitamin A, 0.08 to 0.25 kg of vitamin D3, 0.69 to 2.28 kg of vitamin E, 0.063 to 0.21 kg of vitamin K3, 0.035 to 0.11 kg of vitamin B1, 0.44 to 1.4 kg of vitamin B2, 0.19 to 0.63 kg of vitamin B6, 0.033 to 0.14 kg of vitamin B12, 0.04 to 0.13 kg of folic acid, 0.01 to 0.03 kg of biotin, 0.4 to 1.3 kg of nicotinic acid, 0.1 to 0.38 kg of calcium pantothenate and 1.059 to 2.29 kg of rice hull powder. The laying quails fed by the premix feed have high laying rate, and the ratio of the feed to the egg is 2.2-2.5:1.

The invention discloses a refreshing nutrient milk tea and belongs to the field of beverage formula. Per 100 ml beverage contains 5-20g of soymilk powder, 0.5-3g of coffee powder, 5-20g of cane sugar, 6-8g of codonopsis lanceolata extract, 0.5-1g of American ginseng extract, 0.5-1.4mg of vitamin, 1-2mg of nicotinic acid, 10-50mg of taurine and the balance of water. The beverage provided by the invention has good mouthfeel, low cost, unique flavour, anti-fatigue effect and abundant nutrition.

Intermediate release nicotinic acid formulations exhibiting an in vivo stair-stepped or sigmoidally-shaped absorption curves when the plasma nicotinic acid or nicotinuric acid curves are deconvoluted using the Wagner-Nelson method, which are suitable for oral administration once-a-day preferably during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The stair-stepped or sigmoidal-shaped absorption profiles for nicotinic acid or nicotinuric acid absorbed from the nicotinic acid formulations of the instant invention are characterized by three phases and by the fact that significant quantities of nicotinic acid are absorbed during the first two phases. The first phase generally ends at about 2.3 hours following ingestion and the second phase generally ends at about 7.3 hours after consumption. Approximately 6% of the nicotinic acid dose is generally absorbed by the end of the first phase and approximately 91% of the nicotinic acid dose is absorbed by the end of the second phase.

The invention discloses a composite (E) for disintoxicating and sobering, which is prepared by glucose and fructose, fruit glucose, honey, flower of kudzuvine, hoveniae semoveniae semen, L-alanine, L-ornithine, L-glutamine, L-carnitine according to a certain weight range. In order to enable the effect better, one or more of tea leaf, vitamin C, L-cysteine, taurine, L-asparaginic acid or L-aspartate, vitamin B1, vitamin B6, L-arginine, L-glutamic acid, L-proline, phaseomannite, vitamin B2, nicotinic acid, folic acid, vitamin B12 and pantothenic acid are also added. The composite can be prepared into liquid preparation, electuary and medicinal tea. The composite of the invention can be prepared into food and health food. The invention can quickly disintoxicate, sober, eliminate alcoholism symptom and continued effect of alcohol on a human body, and has no side effect.

The invention relates to a method for preparing 5-methyl-3-bromomethylpyridine hydrobromide. The method comprises a step of preparing methyl 5-methyl nicotinate; a step of preparing 5-methyl-3-pyridinemethanol; a step of preparing 5-methyl-3-pyridinemethanol hydrobromide; and a step of preparing 5-methyl-3-bromomethylpyridine hydrobromide. In the step of preparing methyl 5-methyl nicotinate, esterification of 5-methyl nicotinic acid and thionyl chloride is carried out under heating reflux to obtain methyl 5-methyl nicotinate; in the step of preparing 5-methyl-3-pyridinemethanol, a reduction reaction of methyl 5-methyl nicotinate and sodium borohydride is carried out in an organic solvent to obtain 5-methyl-3-pyridinemethanol; in the step of preparing 5-methyl-3-pyridinemethanol hydrobromide, 5-methyl-3-pyridinemethanol reacts with hydrobromic acid to obtain 5-methyl-3-pyridinemethanol hydrobromide; and in the step of preparing 5-methyl-3-bromomethylpyridine hydrobromide, 5-methyl-3-pyridinemethanol hydrobromide reacts with hydrobromic acid in an organic solvent and water is removed from the reaction system to obtain 5-methyl-3-bromomethylpyridine hydrobromide. According to the method, 5-methyl-3-bromomethylpyridine hydrobromide is obtained by four steps; the process is simple; and yield is high.

The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.

The invention discloses an application of nicotinic acid in preparation of a drug for relieving mammary gland fibrosis of dairy cows through GPR109A receptors. The application comprises the following steps that S1, GPR109A receptor expression difference conditions are analyzed in mammary glands of normal dairy cows and fibrosis-prone dairy cows through in-vivo and in-vitro experiments, and it is determined that the GPR109A receptors are highly expressed in the mammary glands of the dairy cows with mammary gland fibrosis; and S2, fibrosis phenotypes in mammary epithelial cells of the dairy cows are detected, specifically, the change conditions of TGF-beta 1, alpha-SMA, Collagen2 and E-cadherin in the mammary epithelial cells of the dairy cows are specifically and correspondingly detected after the nicotinic acid is relieved. According to the application of nicotinic acid in preparation of the drug for relieving mammary gland fibrosis of the dairy cows through the GPR109A receptors, a brand-new relieving strategy for the mammary gland fibrosis tendency of the dairy cows is formulated, and the relieving effect of nicotinic acid on the mammary gland fibrosis tendency of the dairy cows is comprehensively evaluated by collecting normal mammary gland tissues and mammary gland fibrosis mammary gland tissues, separating primary mammary gland epithelial cells of the dairy cows and utilizing a molecular biology method. Nicotinic acid can effectively reduce rise of fibrosis phenotypes in mammary gland epithelial cells, so that the purpose of preventing the occurrence of mammary gland fibrosis diseases is achieved.